Cancer remains one of the world’s most formidable health challenges, with nearly 10 million cancer-relat...
Bengaluru-based SPARK Radiology, an innovator in medical imaging solutions, has announced the India launch of ...
Mumbai-based Ivory, an early-stage brain health startup, has announced the successful close of its latest $1mi...
With the growth and transformation of the monoclonal antibody (mAb) market, particularly with the recent rapid...
RIPPLE EFFECT of Cancer Drug Duty Cuts
To ease the financial strain on patients, the Union Budget 2025-26 has removed Basic Customs Duty (BCD) on 36 life-saving drugs used for cancer, rare diseases, and chronic conditions. This move is expected to make essential treatments more affordable by lowering overall costs. However, the real question remains: will this truly reduce the financial burden on patients? As prices decrease, what effects will this have on pharmaceutical companies, particularly in terms of sales and competition? Most importantly, how will local players adapt to these changes?
For Feedback, please email us at: communications@mmactiv.com
Sign up here to access BioSpectrum India Flip Book.
Sign up here to access BioSpectrum India Flip Book
